Literature DB >> 16569879

Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50.

Sugunya Utaida1, Richard F Pfeltz, R K Jayaswal, B J Wilkinson.   

Abstract

Whole-cell autolytic activity of prototypical glycopeptide-intermediate Staphylococcus aureus (GISA) Mu50 was reduced versus that of hetero-GISA Mu3 and glycopeptide-susceptible S. aureus, consistent with other GISA strains. In contrast, autolytic activity was relatively high in Mu50 crude cell walls and autolysin extracts against purified cell walls, reflecting the complexities of autolytic activity regulation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569879      PMCID： PMC1426971          DOI： 10.1128/AAC.50.4.1541-1545.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance.

Authors:  Susan Boyle-Vavra; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.

Authors:  Mandy Wootton; Peter M Bennett; Alasdair P MacGowan; Timothy R Walsh
Journal:  J Antimicrob Chemother       Date:  2005-09-12       Impact factor: 5.790

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Molecular characterization of an atl null mutant of Staphylococcus aureus.

Authors:  Junko Takahashi; Hitoshi Komatsuzawa; Sakuo Yamada; Tetsuya Nishida; Harald Labischinski; Tamaki Fujiwara; Masaru Ohara; Jun-ichi Yamagishi; Motoyuki Sugai
Journal:  Microbiol Immunol       Date:  2002       Impact factor: 1.955

6.  Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin.

Authors:  Fionnuala McAleese; Shang Wei Wu; Krzysztof Sieradzki; Paul Dunman; Ellen Murphy; Steven Projan; Alexander Tomasz
Journal:  J Bacteriol       Date:  2006-02       Impact factor: 3.490

7.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

8.  Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.

Authors:  S Boyle-Vavra; R B Carey; R S Daum
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

9.  tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus.

Authors:  Hideki Maki; Nadine McCallum; Markus Bischoff; Akihito Wada; Brigitte Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490
View more
  16 in total

1.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.

Authors:  Adriana Renzoni; Christine Barras; Patrice François; Yvan Charbonnier; Elzbieta Huggler; Christian Garzoni; William L Kelley; Paul Majcherczyk; Jacques Schrenzel; Daniel P Lew; Pierre Vaudaux
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

4.  "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.

Authors:  Michie Saito; Yuki Katayama; Tomomi Hishinuma; Akira Iwamoto; Yoshifumi Aiba; Kyoko Kuwahara-Arai; Longzhu Cui; Miki Matsuo; Nanae Aritaka; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

5.  The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides.

Authors:  Soo-Jin Yang; Arnold S Bayer; Nagendra N Mishra; Michael Meehl; Nagender Ledala; Michael R Yeaman; Yan Q Xiong; Ambrose L Cheung
Journal:  Infect Immun       Date:  2011-10-10       Impact factor: 3.441

6.  Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis.

Authors:  Jennifer L Nelson; Kelly C Rice; Sean R Slater; Paige M Fox; Gordon L Archer; Kenneth W Bayles; Paul D Fey; Barry N Kreiswirth; Greg A Somerville
Journal:  Antimicrob Agents Chemother       Date:  2006-11-27       Impact factor: 5.191

7.  Role of the msaABCR Operon in Cell Wall Biosynthesis, Autolysis, Integrity, and Antibiotic Resistance in Staphylococcus aureus.

Authors:  Bibek G C; Gyan S Sahukhal; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 8.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

9.  Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility.

Authors:  Stewart G Gardner; Darrell D Marshall; Robert S Daum; Robert Powers; Greg A Somerville
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

10.  Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.

Authors:  Michael Meehl; Silvia Herbert; Friedrich Götz; Ambrose Cheung
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.